Topical Application of the PI3Kβ-Selective Small Molecule Inhibitor TGX-221 Is an Effective Treatment Option for Experimental Epidermolysis Bullosa Acquisita

Class I phosphoinositide 3-kinases (PI3K) have been implemented in pathogenesis of experimental epidermolysis bullosa acquisita (EBA), an autoimmune skin disease caused by type VII collagen (COL7) autoantibodies. Mechanistically, inhibition of specific PI3K isoforms, namely PI3Kβ or PI3Kδ, impaired...

Descripción completa

Detalles Bibliográficos
Autores principales: Zillikens, Hannah, Kasprick, Anika, Osterloh, Colin, Gross, Natalie, Radziewitz, Michael, Hass, Cindy, Hartmann, Veronika, Behnen-Härer, Martina, Ernst, Nancy, Boch, Katharina, Vidarsson, Gestur, Visser, Remco, Laskay, Tamás, Yu, Xinhua, Petersen, Frank, Ludwig, Ralf J., Bieber, Katja
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8452940/
https://www.ncbi.nlm.nih.gov/pubmed/34557502
http://dx.doi.org/10.3389/fmed.2021.713312

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8452940/
https://www.ncbi.nlm.nih.gov/pubmed/34557502
http://dx.doi.org/10.3389/fmed.2021.713312

Ejemplares similares